Amy Cutrell

3.0k total citations
18 papers, 1.1k citations indexed

About

Amy Cutrell is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Amy Cutrell has authored 18 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 12 papers in Virology and 4 papers in Emergency Medicine. Recurrent topics in Amy Cutrell's work include HIV/AIDS drug development and treatment (16 papers), HIV/AIDS Research and Interventions (13 papers) and HIV Research and Treatment (12 papers). Amy Cutrell is often cited by papers focused on HIV/AIDS drug development and treatment (16 papers), HIV/AIDS Research and Interventions (13 papers) and HIV Research and Treatment (12 papers). Amy Cutrell collaborates with scholars based in United States, United Kingdom and Germany. Amy Cutrell's co-authors include Helen Steel, Seth Hetherington, Gill Pearce, Odin Naderer, Mounir Ait‐Khaled, Christine Katlama, Gillian Pearce, William Spreen, Jaime E. Hernández and Jane Yeo and has published in prestigious journals such as PLoS ONE, PEDIATRICS and Clinical Pharmacology & Therapeutics.

In The Last Decade

Amy Cutrell

18 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Cutrell United States 13 752 581 253 227 223 18 1.1k
Paul Wannamaker United States 9 705 0.9× 534 0.9× 283 1.1× 116 0.5× 275 1.2× 16 1.1k
Denise Sutherland‐Phillips United States 7 493 0.7× 374 0.6× 273 1.1× 100 0.4× 195 0.9× 13 827
Cindy Brothers United States 7 414 0.6× 295 0.5× 235 0.9× 96 0.4× 167 0.7× 8 723
Britt Stancil United States 9 455 0.6× 329 0.6× 242 1.0× 207 0.9× 67 0.3× 12 850
Claudia Martorell United States 14 467 0.6× 217 0.4× 213 0.8× 598 2.6× 155 0.7× 28 1.3k
Helen Steel United Kingdom 10 305 0.4× 208 0.4× 234 0.9× 157 0.7× 74 0.3× 12 626
Trevor R. Scott United States 10 342 0.5× 257 0.4× 162 0.6× 73 0.3× 74 0.3× 12 615
Inmaculada Jiménez‐Nácher Spain 18 759 1.0× 461 0.8× 67 0.3× 304 1.3× 185 0.8× 27 992
Jean‐Philippe Chave Switzerland 16 864 1.1× 493 0.8× 40 0.2× 499 2.2× 474 2.1× 21 1.3k
S Weller United States 15 450 0.6× 215 0.4× 72 0.3× 547 2.4× 55 0.2× 66 1.1k

Countries citing papers authored by Amy Cutrell

Since Specialization
Citations

This map shows the geographic impact of Amy Cutrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Cutrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Cutrell more than expected).

Fields of papers citing papers by Amy Cutrell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Cutrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Cutrell. The network helps show where Amy Cutrell may publish in the future.

Co-authorship network of co-authors of Amy Cutrell

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Cutrell. A scholar is included among the top collaborators of Amy Cutrell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Cutrell. Amy Cutrell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Parkin, Neil, Fei Gao, Eduard Grebe, et al.. (2022). Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project. Clinical Pharmacology & Therapeutics. 114(1). 29–40. 10 indexed citations
2.
D’Amico, Ronald, Rodica Van Solingen‐Ristea, Bryan Baugh, et al.. (2022). Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy. HIV Medicine. 24(2). 202–211. 35 indexed citations
3.
Han, Kelong, Mark Baker, Mark Lovern, et al.. (2022). Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects. British Journal of Clinical Pharmacology. 88(10). 4607–4622. 32 indexed citations
4.
5.
6.
Cutrell, Amy, Ronald D’Amico, David Dorey, et al.. (2019). 884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies. Open Forum Infectious Diseases. 6(Supplement_2). S20–S20. 4 indexed citations
7.
Cutrell, Amy, Deborah Donnell, David Dunn, et al.. (2017). HIV prevention trial design in an era of effective pre-exposure prophylaxis. HIV Clinical Trials. 18(5-6). 177–188. 16 indexed citations
8.
9.
Brothers, Cindy, Jaime E. Hernández, Amy Cutrell, et al.. (2009). Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(1). 20–28. 133 indexed citations
10.
Symonds, William T., et al.. (2002). Risk factor analysis of hypersensitivity reactions to abacavir. Clinical Therapeutics. 24(4). 565–573. 90 indexed citations
11.
Hetherington, Seth, et al.. (2001). Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clinical Therapeutics. 23(10). 1603–1614. 299 indexed citations
12.
Katlama, Christine, B Clotet, Andreas Plettenberg, et al.. (2001). Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48‐week data from a randomized, double‐blind trial. HIV Medicine. 2(1). 27–34. 11 indexed citations
13.
McMahon, Deborah K., Michael M. Lederman, David W. Haas, et al.. (2001). Antiretroviral Activity and Safety of Abacavir in Combination with Selected HIV-1 Protease Inhibitors in Therapy-Naive HIV-1-Infected Adults. Antiviral Therapy. 6(2). 105–114. 17 indexed citations
14.
15.
Lederman, Michael M., Ray A. McKinnis, Dennis Kelleher, et al.. (2000). Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 14(17). 2635–2642. 69 indexed citations
16.
Miller, Veronica, Mounir Ait‐Khaled, Christopher Stone, et al.. (2000). HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS. 14(2). 163–171. 107 indexed citations
17.
Katlama, Christine, Bonaventura Clotet, Andreas Plettenberg, et al.. (2000). The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. AIDS. 14(7). 781–789. 49 indexed citations
18.
Katlama, Christine, Thomas Harrer, Patrice Massip, et al.. (1998). A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS. 12(16). F197–F202. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Wannamaker Breakdown of academic impact, for papers by Denise Sutherland‐Phillips Breakdown of academic impact, for papers by Cindy Brothers Breakdown of academic impact, for papers by Britt Stancil Breakdown of academic impact, for papers by Claudia Martorell Breakdown of academic impact, for papers by Helen Steel Breakdown of academic impact, for papers by Trevor R. Scott Breakdown of academic impact, for papers by Inmaculada Jiménez‐Nácher Breakdown of academic impact, for papers by Jean‐Philippe Chave Breakdown of academic impact, for papers by S Weller
Rankless by CCL
2026